PLSE Pulse Biosciences Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: PLSE

Price (delayed)

$51.98

Market cap

$3.71B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.18

Enterprise value

$3.61B

Sign up for free to view scoring metrics ?
Relative Growth: Rel. Growth:
Relative Strength: Rel. Strength:
Relative Valuation: Rel. Valuation:
Relative Profitability: Rel. Profitability: 4

® Pulse Biosciences is a novel bioelectric medicine company committed to health innovation that has the intention as well as the potential to improve the quality of life for patients. ...

Highlights
The company's gross profit has surged by 102% QoQ
The gross margin has surged by 101% since the previous quarter
PLSE's equity has soared by 50% since the previous quarter but it is down by 4.8% year-on-year
The quick ratio has increased by 33% since the previous quarter but it has declined by 22% year-on-year
The net income has declined by 18% year-on-year and by 7% since the previous quarter
PLSE's EPS is down by 11% year-on-year and by 7% since the previous quarter
Sector: Healthcare
Industry: Medical Instruments & Supplies
Website: http://www.pulsebiosciences.com
Peers: OBIO OM

Key stats

What are the main financial stats of PLSE

PLSE stock price

How has the Pulse Biosciences stock price performed over time
Intraday
-1.35%
1 week
4.78%
1 month
3.09%
1 year
193.67%
YTD
278.59%
QTD
87.45%

Financial performance

How have Pulse Biosciences's revenue and profit performed over time
Revenue
$1.19M
Gross profit
$3,000
Operating income
-$83.04M
Net income
-$80.06M
Gross margin
0.3%
Net margin
-6,755.8%
The company's gross profit has surged by 102% QoQ
The gross margin has surged by 101% since the previous quarter
The company's revenue has surged by 58% QoQ
The operating margin has grown by 33% from the previous quarter

Price vs fundamentals

How does PLSE's price correlate with its fundamentals

Growth

What is Pulse Biosciences's growth rate over time

Valuation

What is Pulse Biosciences stock price valuation
P/E
N/A
P/B
36.16
P/S
3,035.46
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
3,048.52
PLSE's EPS is down by 11% year-on-year and by 7% since the previous quarter
The P/B is 122% above the last 4 quarters average of 16.5
PLSE's equity has soared by 50% since the previous quarter but it is down by 4.8% year-on-year
The company's revenue has surged by 58% QoQ
The stock's price to sales (P/S) is 39% less than its last 4 quarters average of 5021.7

Efficiency

How efficient is Pulse Biosciences business performance
The ROIC has declined by 50% year-on-year and by 16% since the previous quarter
PLSE's return on equity is down by 45% year-on-year and by 9% since the previous quarter
The ROA has contracted by 41% YoY and by 9% from the previous quarter
PLSE's return on sales is up by 32% since the previous quarter

Dividends

What is PLSE's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for PLSE.

Financial health

How did Pulse Biosciences financials performed over time
The company's total assets rose by 42% QoQ but it fell by 3.9% YoY
The quick ratio has increased by 33% since the previous quarter but it has declined by 22% year-on-year
The company's debt is 93% lower than its equity
PLSE's equity has soared by 50% since the previous quarter but it is down by 4.8% year-on-year
The debt to equity has contracted by 36% from the previous quarter and by 13% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.